linvoseltamab-gcpt

linvoseltamab-gcpt (LYNOZYFIC) is an FDA-listed pharmaceutical active ingredient. Associated with enGene Therapeutics. Route of administration: injection. Current US regulatory status: approved.

LYNOZYFIC is a marketed brand name for linvoseltamab-gcpt. Check FDA Drugs@FDA for the current US label holder and prescribing information.

linvoseltamab-gcpt has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.